NASDAQ:PACB - Pacific Biosciences of California Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$2.58 -0.05 (-1.90 %)
(As of 05/25/2018 03:08 AM ET)
Previous Close$2.63
Today's Range$2.57 - $2.66
52-Week Range$2.02 - $5.70
Volume329,648 shs
Average Volume970,498 shs
Market Capitalization$344.20 million
P/E Ratio-2.97
Dividend YieldN/A
Beta1.58

About Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California logoPacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company's single molecule real-time (SMRT) sequencing technology enables single molecule real-time detection of biological processes. It offers PacBio RS II and Sequel Systems that conducts, monitors, and analyzes single molecule biochemical reactions in real time. The company also provides consumable products, including SMRT cells, as well as various reagent kits, such as template preparation, binding, and sequencing kits. Its customers include research institutions; commercial laboratories; genome centers; clinical, government, and academic institutions; genomics service providers; pharmaceutical companies; and agricultural companies. The company markets its products through a direct sales force in North America and Europe, as well as primarily through distribution partners in Asia, the Middle East, and Latin America. The company was formerly known as Nanofluidics, Inc. Pacific Biosciences of California, Inc. was founded in 2000 and is headquartered in Menlo Park, California.

Receive PACB News and Ratings via Email

Sign-up to receive the latest news and ratings for PACB and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Analytical instruments
Sub-IndustryLife Sciences Tools & Services
SectorMedical
SymbolNASDAQ:PACB
CUSIP69404D10
Phone650-521-8000

Debt

Debt-to-Equity Ratio0.14
Current Ratio4.64
Quick Ratio3.60

Price-To-Earnings

Trailing P/E Ratio-2.97
Forward P/E Ratio-4.10
P/E GrowthN/A

Sales & Book Value

Annual Sales$93.47 million
Price / Sales3.64
Cash FlowN/A
Price / CashN/A
Book Value$0.78 per share
Price / Book3.31

Profitability

EPS (Most Recent Fiscal Year)($0.87)
Net Income$-92,180,000.00
Net Margins-105.22%
Return on Equity-91.11%
Return on Assets-58.10%

Miscellaneous

Employees456
Outstanding Shares131,880,000

Pacific Biosciences of California (NASDAQ:PACB) Frequently Asked Questions

What is Pacific Biosciences of California's stock symbol?

Pacific Biosciences of California trades on the NASDAQ under the ticker symbol "PACB."

How were Pacific Biosciences of California's earnings last quarter?

Pacific Biosciences of California (NASDAQ:PACB) released its quarterly earnings results on Wednesday, May, 2nd. The biotechnology company reported ($0.20) EPS for the quarter, missing the Zacks' consensus estimate of ($0.19) by $0.01. The biotechnology company earned $19.40 million during the quarter, compared to analysts' expectations of $23.97 million. Pacific Biosciences of California had a negative return on equity of 91.11% and a negative net margin of 105.22%. Pacific Biosciences of California's quarterly revenue was down 22.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.26) EPS. View Pacific Biosciences of California's Earnings History.

When is Pacific Biosciences of California's next earnings date?

Pacific Biosciences of California is scheduled to release their next quarterly earnings announcement on Tuesday, July, 31st 2018. View Earnings Estimates for Pacific Biosciences of California.

What price target have analysts set for PACB?

2 brokerages have issued twelve-month price targets for Pacific Biosciences of California's shares. Their predictions range from $4.00 to $6.80. On average, they expect Pacific Biosciences of California's share price to reach $5.40 in the next year. View Analyst Ratings for Pacific Biosciences of California.

Who are some of Pacific Biosciences of California's key competitors?

Who are Pacific Biosciences of California's key executives?

Pacific Biosciences of California's management team includes the folowing people:
  • Dr. Michael W. Hunkapiller, Exec. Chairman, CEO & Pres (Age 69)
  • Ms. Susan K. Barnes, Sr. VP & CFO (Age 64)
  • Mr. James Michael Phillips, Sr. VP of R&D (Age 67)
  • Mr. Kevin P. Corcoran, Sr. VP of Market Devel. (Age 59)
  • Ms. Kathy P. Ordoñez, Chief Commercial Officer, Exec. VP & Director (Age 67)

Has Pacific Biosciences of California been receiving favorable news coverage?

Media stories about PACB stock have been trending somewhat positive recently, according to Accern. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Pacific Biosciences of California earned a media sentiment score of 0.04 on Accern's scale. They also assigned news articles about the biotechnology company an impact score of 46.55 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next few days.

Who are Pacific Biosciences of California's major shareholders?

Pacific Biosciences of California's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.67%), Blackstone Group L.P. (3.13%), Point72 Asset Management L.P. (1.59%), Northern Trust Corp (1.00%), Trellus Management Company LLC (0.59%) and Schwab Charles Investment Management Inc. (0.39%). View Institutional Ownership Trends for Pacific Biosciences of California.

Which institutional investors are selling Pacific Biosciences of California stock?

PACB stock was sold by a variety of institutional investors in the last quarter, including Wells Fargo & Company MN. View Insider Buying and Selling for Pacific Biosciences of California.

Which institutional investors are buying Pacific Biosciences of California stock?

PACB stock was bought by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Blackstone Group L.P., BlackRock Inc., Citadel Advisors LLC, Millennium Management LLC, UBS Group AG, Trellus Management Company LLC and Northern Trust Corp. View Insider Buying and Selling for Pacific Biosciences of California.

How do I buy shares of Pacific Biosciences of California?

Shares of PACB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Pacific Biosciences of California's stock price today?

One share of PACB stock can currently be purchased for approximately $2.58.

How big of a company is Pacific Biosciences of California?

Pacific Biosciences of California has a market capitalization of $344.20 million and generates $93.47 million in revenue each year. The biotechnology company earns $-92,180,000.00 in net income (profit) each year or ($0.87) on an earnings per share basis. Pacific Biosciences of California employs 456 workers across the globe.

How can I contact Pacific Biosciences of California?

Pacific Biosciences of California's mailing address is 1305 O`BRIEN DRIVE, MENLO PARK CA, 94025. The biotechnology company can be reached via phone at 650-521-8000 or via email at [email protected]


MarketBeat Community Rating for Pacific Biosciences of California (PACB)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  187 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  389
MarketBeat's community ratings are surveys of what our community members think about Pacific Biosciences of California and other stocks. Vote "Outperform" if you believe PACB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PACB will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Pacific Biosciences of California (NASDAQ:PACB) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
2 Wall Street analysts have issued ratings and price targets for Pacific Biosciences of California in the last 12 months. Their average twelve-month price target is $5.40, suggesting that the stock has a possible upside of 109.30%. The high price target for PACB is $6.80 and the low price target for PACB is $4.00. There are currently 2 hold ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.002.332.332.33
Ratings Breakdown: 0 Sell Rating(s)
2 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $5.40$6.2667$6.2667$6.2667
Price Target Upside: 109.30% upside55.50% upside55.50% upside55.50% upside

Pacific Biosciences of California (NASDAQ:PACB) Consensus Price Target History

Price Target History for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/3/2017First AnalysisDowngradeOverweight ➝ Equal Weight$4.00N/AView Rating Details
9/28/2017CL KingDowngradeBuy ➝ Neutral$6.80HighView Rating Details
4/27/2017Cantor FitzgeraldSet Price TargetBuy$8.00MediumView Rating Details
11/3/2016JPMorgan Chase & Co.Reiterated RatingHold$12.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Pacific Biosciences of California (NASDAQ:PACB) Earnings History and Estimates Chart

Earnings by Quarter for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ:PACB) Earnings Estimates

2018 EPS Consensus Estimate: ($0.66)
2019 EPS Consensus Estimate: ($0.46)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20182($0.19)($0.19)($0.19)
Q2 20182($0.18)($0.17)($0.18)
Q3 20182($0.17)($0.16)($0.17)
Q4 20182($0.13)($0.13)($0.13)
Q1 20191($0.14)($0.14)($0.14)
Q2 20191($0.13)($0.13)($0.13)
Q3 20191($0.10)($0.10)($0.10)
Q4 20191($0.09)($0.09)($0.09)

Pacific Biosciences of California (NASDAQ PACB) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/31/2018($0.17)N/AView Earnings Details
5/2/2018Q1 2018($0.19)($0.20)$23.97 million$19.40 millionViewListenView Earnings Details
2/1/2018Q4 2017($0.1960)($0.18)$21.89 million$24.94 millionViewListenView Earnings Details
11/2/2017Q3 2017($0.20)($0.19)$28.29 million$23.54 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.24)($0.26)$23.34 million$20.07 millionViewListenView Earnings Details
4/26/2017Q1 2017($0.23)($0.26)$23.80 million$24.90 millionViewN/AView Earnings Details
2/2/2017Q416($0.23)($0.21)$22.84 million$25.70 millionViewListenView Earnings Details
11/2/2016Q316($0.20)($0.19)$24.68 million$25.10 millionViewN/AView Earnings Details
8/4/2016Q2($0.22)($0.21)$20.19 million$20.70 millionViewN/AView Earnings Details
4/21/2016Q1($0.25)($0.23)$18.02 million$19.10 millionViewListenView Earnings Details
2/3/2016Q4($0.02)($0.02)$36.96 million$36.28 millionViewN/AView Earnings Details
10/22/2015Q3($0.27)$0.02$15.84 million$13.90 millionViewListenView Earnings Details
8/5/2015Q215($0.14)($0.16)$26.36 million$24.94 millionViewListenView Earnings Details
5/5/2015Q115($0.27)($0.27)$13.70 million$17.65 millionViewN/AView Earnings Details
2/3/2015Q414($0.26)($0.26)$14.90 million$16.90 millionViewListenView Earnings Details
10/23/2014Q214($0.16)($0.13)$17.20 million$20.60 millionViewListenView Earnings Details
7/24/2014Q114($0.15)($0.27)$11.39 million$11.40 millionViewN/AView Earnings Details
4/30/2014($0.28)($0.28)$10.17 million$11.64 millionViewN/AView Earnings Details
2/4/2014Q413($0.27)($0.26)$9.13 million$9.10 millionViewN/AView Earnings Details
10/22/2013Q313($0.30)($0.31)$7.08 million$7.40 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.35)($0.33)$6.09 million$6.04 millionViewN/AView Earnings Details
4/23/2013Q1 2013($0.37)($0.37)$4.28 million$5.60 millionViewN/AView Earnings Details
2/5/2013Q4 2012($0.37)($0.39)$4.38 million$5.90 millionViewN/AView Earnings Details
10/25/2012($0.45)($0.41)ViewN/AView Earnings Details
7/26/2012($0.46)($0.40)ViewN/AView Earnings Details
5/1/2012($0.47)($0.50)ViewN/AView Earnings Details
2/7/2012($0.50)($0.42)ViewN/AView Earnings Details
10/27/2011Q3 2011($0.60)($0.45)ViewN/AView Earnings Details
8/4/2011($0.63)($0.42)ViewN/AView Earnings Details
4/27/2011($0.67)($0.66)ViewN/AView Earnings Details
2/15/2011($0.91)($0.97)ViewN/AView Earnings Details
11/30/2010Q3 2010($39.70)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Pacific Biosciences of California (NASDAQ:PACB) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Pacific Biosciences of California (NASDAQ PACB) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 70.49%
Insider Trading History for Pacific Biosciences of California (NASDAQ:PACB)
Insider Trading History for Pacific Biosciences of California (NASDAQ:PACB)

Pacific Biosciences of California (NASDAQ PACB) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/28/2016James Michael PhillipsSVPSell20,000$8.44$168,800.00201,449View SEC Filing  
7/29/2016James Michael PhillipsSVPSell20,000$8.45$169,000.00198,949View SEC Filing  
4/25/2016James Michael PhillipsSVPSell20,000$10.29$205,800.00201,449View SEC Filing  
3/2/2015Brian B DowVPBuy2,503$4.91$12,289.73View SEC Filing  
3/2/2015Kevin P CorcoranSVPBuy2,816$4.91$13,826.56View SEC Filing  
8/19/2014William W EricsonDirectorBuy39,299$5.14$201,996.86View SEC Filing  
8/18/2014William W EricsonDirectorBuy135,155$5.09$687,938.95View SEC Filing  
8/14/2014William W EricsonDirectorBuy77,822$5.00$389,110.00View SEC Filing  
8/13/2014William W EricsonDirectorBuy29,435$4.93$145,114.55View SEC Filing  
8/12/2014William W EricsonDirectorBuy123,423$4.89$603,538.47View SEC Filing  
12/12/2013Michael HunkapillerCEOBuy100,000$4.13$413,000.001,800,000View SEC Filing  
11/21/2013Michael HunkapillerCEOBuy200,000$3.61$722,000.001,700,000View SEC Filing  
12/3/2012Michael HunkapillerCEOBuy154,100$1.75$269,675.00View SEC Filing  
11/29/2012Michael HunkapillerCEOBuy242,200$1.68$406,896.00View SEC Filing  
11/26/2012Michael HunkapillerCEOBuy186,400$1.44$268,416.00View SEC Filing  
11/20/2012Michael HunkapillerCEOBuy155,000$1.27$196,850.00View SEC Filing  
11/16/2012Michael HunkapillerCEOBuy262,300$1.16$304,268.00View SEC Filing  
8/7/2012Michael HunkapillerCEOBuy400,000$1.75$700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Pacific Biosciences of California (NASDAQ PACB) News Headlines

Source:
DateHeadline
Analyzing Mettler-Toledo International (MTD) & Pacific Biosciences of California (PACB)Analyzing Mettler-Toledo International (MTD) & Pacific Biosciences of California (PACB)
www.americanbankingnews.com - May 23 at 9:20 PM
Phase Genomics and Pacific Biosciences Announce the Release of Co-Developed Genome Assembly Phasing Software - FALCON-PhasePhase Genomics and Pacific Biosciences Announce the Release of Co-Developed Genome Assembly Phasing Software - 'FALCON-Phase'
www.prnewswire.com - May 21 at 8:51 PM
Pacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.05 MillionPacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.05 Million
www.americanbankingnews.com - May 19 at 4:19 AM
Pacific Biosciences (PACB) versus Bruker (BRKR) Critical ContrastPacific Biosciences (PACB) versus Bruker (BRKR) Critical Contrast
www.americanbankingnews.com - May 17 at 11:16 PM
Zacks: Analysts Expect Pacific Biosciences (PACB) Will Post Earnings of -$0.16 Per ShareZacks: Analysts Expect Pacific Biosciences (PACB) Will Post Earnings of -$0.16 Per Share
www.americanbankingnews.com - May 17 at 10:17 AM
The Clock Is Ticking Louder As PacBio Must Generate More Revenue And Shrink Its Cash Burn RateThe Clock Is Ticking Louder As PacBio Must Generate More Revenue And Shrink Its Cash Burn Rate
seekingalpha.com - May 15 at 5:02 PM
pSivida (EYPT) & Pacific Biosciences (PACB) Critical ReviewpSivida (EYPT) & Pacific Biosciences (PACB) Critical Review
www.americanbankingnews.com - May 15 at 10:46 AM
Pacific Bio (PACB) Announces Favorable Outcome in UK and German Patent Litigation Against Oxford NanoporePacific Bio (PACB) Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore
www.streetinsider.com - May 9 at 9:17 AM
Pacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford NanoporePacific Biosciences Announces Favorable Outcome in UK and German Patent Litigation Against Oxford Nanopore
finance.yahoo.com - May 9 at 9:17 AM
Research Analysts Set Expectations for Pacific Biosciences Q4 2018 Earnings (PACB)Research Analysts Set Expectations for Pacific Biosciences' Q4 2018 Earnings (PACB)
www.americanbankingnews.com - May 7 at 4:18 AM
Here's Why Pacific Biosciences of California Is Falling TodayHere's Why Pacific Biosciences of California Is Falling Today
finance.yahoo.com - May 3 at 4:36 PM
For Pacific Biosciences of California, a First Quarter Hurt by Shipment DelaysFor Pacific Biosciences of California, a First Quarter Hurt by Shipment Delays
finance.yahoo.com - May 3 at 4:36 PM
Heres Why Pacific Biosciences of California Is Falling TodayHere's Why Pacific Biosciences of California Is Falling Today
www.fool.com - May 3 at 1:21 PM
Benzingas Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 MissBenzinga's Daily Biotech Pulse: Achaogen Slumps On Mixed FDA Panel Vote, Pacific Biosciences Sinks On Q1 Miss
feeds.benzinga.com - May 3 at 9:36 AM
Pacific Biosciences of Californias (PACB) CEO Mike Hunkapiller on Q1 2018 Results - Earnings Call TranscriptPacific Biosciences of California's (PACB) CEO Mike Hunkapiller on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 9:06 AM
Edited Transcript of PACB earnings conference call or presentation 2-May-18 8:30pm GMTEdited Transcript of PACB earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 9:06 AM
Pacific Biosciences: 1Q Earnings SnapshotPacific Biosciences: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 9:06 AM
Pacific Biosciences (PACB) Upgraded to Sell by ValuEnginePacific Biosciences (PACB) Upgraded to Sell by ValuEngine
www.americanbankingnews.com - May 2 at 10:58 PM
Pacific Biosciences (PACB) Announces  Earnings Results, Misses Expectations By $0.01 EPSPacific Biosciences (PACB) Announces Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 10:02 PM
Pacific Biosciences of California, Inc. Announces First Quarter 2018 Financial ResultsPacific Biosciences of California, Inc. Announces First Quarter 2018 Financial Results
finance.yahoo.com - May 2 at 4:43 PM
$24.58 Million in Sales Expected for Pacific Biosciences (PACB) This Quarter$24.58 Million in Sales Expected for Pacific Biosciences (PACB) This Quarter
www.americanbankingnews.com - May 1 at 2:20 AM
Zacks: Analysts Expect Pacific Biosciences (PACB) Will Post Earnings of -$0.19 Per ShareZacks: Analysts Expect Pacific Biosciences (PACB) Will Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 29 at 7:20 PM
Cracking the Code of Life—at Light SpeedCracking the Code of Life—at Light Speed
www.wsj.com - April 28 at 4:36 PM
Pacific Biosciences (PACB) Set to Announce Quarterly Earnings on WednesdayPacific Biosciences (PACB) Set to Announce Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 25 at 9:50 AM
GENEWIZ And Pacific Biosciences Announce Winner Of The 2017 Structural Variant SMRT® Grant ProgramGENEWIZ And Pacific Biosciences Announce Winner Of The 2017 Structural Variant SMRT® Grant Program
finance.yahoo.com - April 24 at 4:52 PM
Next Generation Sequencing (NGS) Global Market 2018-2023 to Grow at a CAGR of 20.21%Next Generation Sequencing (NGS) Global Market 2018-2023 to Grow at a CAGR of 20.21%
www.prnewswire.com - April 23 at 4:35 PM
Can Core Unit Drive Pacific Biosciences (PACB) Q1 Earnings?Can Core Unit Drive Pacific Biosciences' (PACB) Q1 Earnings?
www.msn.com - April 20 at 9:23 AM
Pacific Biosciences (PACB) Scheduled to Post Quarterly Earnings on TuesdayPacific Biosciences (PACB) Scheduled to Post Quarterly Earnings on Tuesday
www.americanbankingnews.com - April 17 at 2:49 AM
Pacific Biosciences (PACB) Receives Average Recommendation of "Hold" from AnalystsPacific Biosciences (PACB) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - April 16 at 1:44 AM
Pacific Biosciences (PACB) Stock Rating Lowered by BidaskClubPacific Biosciences (PACB) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 15 at 12:35 PM
Head to Head Contrast: Pacific Biosciences (PACB) versus Integra lifesciences (IART)Head to Head Contrast: Pacific Biosciences (PACB) versus Integra lifesciences (IART)
www.americanbankingnews.com - April 15 at 7:21 AM
Pacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.23 MillionPacific Biosciences (PACB) Expected to Announce Quarterly Sales of $24.23 Million
www.americanbankingnews.com - April 14 at 2:21 AM
BidaskClub Upgrades Pacific Biosciences (PACB) to "Hold"BidaskClub Upgrades Pacific Biosciences (PACB) to "Hold"
www.americanbankingnews.com - April 13 at 10:45 AM
Pacific Biosciences Gains as HudsonAlpha Picks Sequel SystemPacific Biosciences Gains as HudsonAlpha Picks Sequel System
finance.yahoo.com - April 13 at 9:33 AM
Short Interest in Pacific Biosciences (PACB) Decreases By 19.4%Short Interest in Pacific Biosciences (PACB) Decreases By 19.4%
www.americanbankingnews.com - April 13 at 3:23 AM
Pacific Biosciences (PACB) Expected to Post Earnings of -$0.19 Per SharePacific Biosciences (PACB) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - April 12 at 7:21 PM
Pacific Biosciences (PACB) Upgraded to "Sell" by BidaskClubPacific Biosciences (PACB) Upgraded to "Sell" by BidaskClub
www.americanbankingnews.com - April 12 at 6:14 PM
Pacific Biosciences (PACB) Downgraded to Hold at Zacks Investment ResearchPacific Biosciences (PACB) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 12 at 11:07 AM
Pacific Biosciences (PACB) Upgraded at Zacks Investment ResearchPacific Biosciences (PACB) Upgraded at Zacks Investment Research
www.americanbankingnews.com - April 11 at 9:52 AM
HudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities ResearchHudsonAlpha Using PacBio Sequencing for Childhood Developmental Disabilities Research
finance.yahoo.com - April 11 at 9:51 AM
Pacific Biosciences: A Shovel Supplier To The Genomics MegatrendPacific Biosciences: A Shovel Supplier To The Genomics Megatrend
seekingalpha.com - April 10 at 4:40 PM
Genome Sequencing RoundupGenome Sequencing Roundup
seekingalpha.com - April 2 at 4:40 PM
Zacks: Brokerages Anticipate Pacific Biosciences of California (PACB) Will Post Quarterly Sales of $24.23 MillionZacks: Brokerages Anticipate Pacific Biosciences of California (PACB) Will Post Quarterly Sales of $24.23 Million
www.americanbankingnews.com - March 28 at 2:50 AM
Pacific Biosciences Announces Ten-Unit Sequel System Order for AnnoroadPacific Biosciences Announces Ten-Unit Sequel System Order for Annoroad
finance.yahoo.com - March 27 at 9:38 AM
Pacific Biosciences of California (PACB) Expected to Post Earnings of -$0.19 Per SharePacific Biosciences of California (PACB) Expected to Post Earnings of -$0.19 Per Share
www.americanbankingnews.com - March 26 at 9:12 PM
Health Care Sector Update for 03/23/2018: PACB, PGNX, PFE, GSK, VTVT - NasdaqHealth Care Sector Update for 03/23/2018: PACB, PGNX, PFE, GSK, VTVT - Nasdaq
www.nasdaq.com - March 23 at 4:40 PM
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore - GlobeNewswire (press release)Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore - GlobeNewswire (press release)
globenewswire.com - March 22 at 4:41 PM
Pacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford NanoporePacific Biosciences Prevails in Patent Eligibility Ruling Against Oxford Nanopore
finance.yahoo.com - March 22 at 4:41 PM
Pacific Biosciences of California (PACB) Receives Average Recommendation of "Hold" from AnalystsPacific Biosciences of California (PACB) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 22 at 1:52 AM
Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy ProtocolsStudy Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols
finance.yahoo.com - March 15 at 9:06 AM

SEC Filings

Pacific Biosciences of California (NASDAQ:PACB) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Pacific Biosciences of California (NASDAQ:PACB) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Pacific Biosciences of California (NASDAQ PACB) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.